PORTAGE, Mich., July 29, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its next-generation InThrill Thrombectomy System, the first and only purpose-built small vessel and arteriovenous (AV) access thrombectomy system that can deliver fast, full luminal clot removal. The next-generation InThrill Thrombectomy System, the first and only purpose-built small vessel and arteriovenous (AV) access thrombectomy system that ca ...

MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of th ...

业绩总结 - 2025年第二季度订单收入增长6%，订单总额同比增长7%[11] - 销售额同比增长1%，主要受个人健康业务推动，诊断与治疗及连接护理业务表现有所抵消[11] - 2025年第二季度销售额为20.84亿欧元，较2024年同期的21.74亿欧元下降1%[23] - 个人健康业务销售额为8.62亿欧元，同比增长6%[38] - 连接护理业务销售额为12.72亿欧元，同比下降1%[30] - 2025年调整后EBITA利润率提高130个基点至12.4%[11] - 2025年调整后EBITA利润率范围上调50个基点至11.3%-11.8%[11] 现金流与债务 - 自由现金流从略微正增长至2亿至4亿欧元，扣除Respironics和解费用[11] - 2025年自由现金流预期修正为2亿至4亿欧元[48] - 2025年总净债务为66亿欧元，长期债务的平均期限为6.2年[65] 未来展望 - 预计2025年可比销售增长维持在1%-3%[48] - 2025年第三季度集团和业务部门的外汇翻译预计下降约5.5%[50] - 2025年全年外汇翻译预计下降约3.5%-4.0%[50] - 2025年有效税率预计在24%-26%之间[50] - 2025年财务收入和支出预计为约-2.6亿欧元[50] 费用与支出 - 2025年第二季度净资本支出为-1.56亿欧元，折旧为-1.49亿欧元[66] - 2024年全年重组和收购相关费用为3.26亿欧元[67] - 2025年第二季度重组费用为4300万欧元，收购相关费用为300万欧元[67] 其他信息 - 2025年“其他”部门销售预计在1.3亿至1.4亿欧元之间，全年销售预计在5.4亿至5.7亿欧元之间[50] - 2025年调整后的EBITA预计持平，EBITA预计为约-6,500万欧元[50]

Ekso Bionics (EKSO) Q2 2025 Earnings Call July 28, 2025 04:30 PM ET Company ParticipantsStephen Kilmer - Investor RelationsJerome Wong - CFOScott Davis - CEO & DirectorConference Call ParticipantsBen Haynor - MD & Senior Research AnalystSwayampakula Ramakanth - Managing Director & Senior Equity AnalystOperatorGreetings, and welcome to the Ekso Bionics Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session w ...

Ekso Bionics (EKSO) Q2 2025 Earnings Call July 28, 2025 04:30 PM ET Speaker0Greetings, and welcome to the Ekso Bionics Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. It is now my pleasure to introduce your host, Stephen Kilmore, Investor Relations. Thank you.You may begin.Speaker1Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics relea ...

VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 8, 2025, at 6:30 a.m. Australian Eastern Standa ...

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents comprehensive 12- ...

Key Takeaways BAX expects 4%-5% reported sales growth in Q2, led by strong execution in core business segments.BAX saw 6% operational growth in MPT and HST segments in Q1, both exceeding the companys expectations.BAX projects stable Q2 margins with EPS of $0.59-$0.63, aided by recovery and cost containment efforts.Baxter International Inc. (BAX) is scheduled to release second-quarter 2025 results on July 31, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consens ...

财务表现 - 2025年第二季度营收达50.6亿美元，超出分析师预期的48.9亿美元，同比增长22.8% [1][2][5] - 调整后每股收益为0.75美元，高于预期的0.73美元，同比增长21% [1][2] - 心血管板块营收33.5亿美元，同比增长26.8%，其中心脏病学业务表现突出，增长29.3% [2][5] - 医疗外科板块营收17.2亿美元，同比增长15.7%，但内生增长放缓，内窥镜和泌尿科内生销售分别增长7.8%和6.3% [2][6] - 美国市场表现强劲，营收增长30.7%，欧洲和拉美/加拿大分别增长6.8%和4.0% [9] 业务亮点 - 心血管设备驱动业绩增长，主要产品包括WATCHMAN FLX左心耳封堵器和FARAPULSE脉冲场消融导管平台 [3][5] - FARAPULSE获FDA批准扩大适应症范围，WATCHMAN FLX Pro在欧洲获得CE认证 [8] - 完成两项战略收购：Intera Oncology（肝癌化疗泵）和SoniVie（超声引导高血压治疗设备） [8] - 毛利率提升至34.24亿美元，GAAP净利润达7.97亿美元，调整后净利润11.3亿美元 [7] 战略与展望 - 公司战略聚焦核心心脏和外科设备领域，同时通过研发和收购拓展高增长疗法 [4][12] - 上调2025年全年指引：预计营收增长18-19%（内生增长14-15%），调整后每股收益2.95-2.99美元 [11] - 预计2025年下半年将面临2亿美元关税影响，计划通过收入增长和削减 discretionary 支出来抵消 [1][11] - 未来重点关注医疗外科板块内生增长、关税影响、国际市场表现及新产品临床进展 [12] 一次性项目 - 重组费用8300万美元（主要来自停产生主动脉瓣产品线），无形资产减值4600万美元 [10]

评级升级与投资机会 - West Pharmaceutical Services (WST) 近期被上调至 Zacks Rank 1 (强力买入)，反映其盈利预期的上升趋势，这是影响股价的最强动力之一 [1] - Zacks 评级唯一依据是公司盈利预期的变化，系统追踪当前及未来年度卖方分析师的每股收益(EPS)共识预期 [2] - 盈利预期的变化与股价短期走势高度相关，机构投资者通过调整估值模型中的盈利预期来推动买卖行为，进而影响股价 [5] Zacks 评级系统特点 - Zacks 评级系统基于盈利预期修订的四个因素，将股票分为五类，排名前5%的股票获"强力买入"评级，历史数据显示这类股票自1988年以来年均回报率达+25% [8] - 该系统覆盖超过4000只股票，始终保持"买入"与"卖出"评级比例均衡，仅前20%的股票因盈利预期修订优势被视为短期跑赢市场的候选标的 [10][11] West Pharmaceutical 盈利预期变化 - 市场预期该公司2025财年每股收益为6.61美元，与上年持平，但过去三个月Zacks共识预期已上调7.8% [9] - 盈利预期持续上调及评级升级表明公司基本面改善，投资者可能推动股价进一步上涨 [6] 盈利预期修订与投资决策 - 实证研究表明盈利预期修订趋势与股价短期波动强相关，Zacks 评级系统通过有效捕捉这一关系辅助投资决策 [7] - West Pharmaceutical 进入Zacks覆盖股票前5%，意味着其盈利预期修订表现优异，短期内股价可能走强 [11]